Literature DB >> 10564718

Expression and intracellular processing of chimeric and mutant CFTR molecules.

J F Pollet1, J Van Geffel, E Van Stevens, R Van Geffel, R Beauwens, A Bollen, P Jacobs.   

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) is a cyclic AMP-activated chloride channel comprising two membrane-spanning domains (MSDs), two nucleotide-binding domains (NBDs) and a unique regulatory (R) domain. The most frequent cystic fibrosis (CF) mutation, a deletion of Phe508 in NBD1, results in the retention of the DeltaF508 CFTR in the endoplasmic reticulum, as do many other natural or constructed mutations located within the first NBD. In order to further define the role of NBD1 in CFTR folding and to determine whether the higher frequency of mutations in NBD1 with respect to NBD2 results from its position in the molecule or is related to its primary sequence, we constructed and expressed chimeric CFTRs wherein NBD domains were either exchanged or deleted. Synthesis, maturation and activity of the chimeras were assessed by Western blotting and iodide efflux assay after transient or stable expression in COS-1 or CHO cells respectively. The data showed that deletion of NBD1 prevented transport of CFTR to the cytoplasmic membrane whereas deletion of NBD2 did not impair this process but resulted in an inactive chloride channel. On the other hand, substituting or inverting NBDs in the CFTR molecule impaired its processing. In addition, while the NBD1 R555K mutation is known to partially correct the processing of CFTR DeltaF508 and to increase activity of both wild-type and DeltaF508 individual channels, it showed no positive effect when introduced into the double NBD1 chimera. Taken together, these observations suggest that the proper folding process of CFTR results from complex interactions between NBDs and their surrounding domains (MSDs and/or R domain).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10564718     DOI: 10.1016/s0925-4439(99)00088-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Stabilization of Nucleotide Binding Domain Dimers Rescues ABCC6 Mutants Associated with Pseudoxanthoma Elasticum.

Authors:  Yanchao Ran; Patrick H Thibodeau
Journal:  J Biol Chem       Date:  2016-12-19       Impact factor: 5.157

2.  A spectrum of ABCC6 mutations is responsible for pseudoxanthoma elasticum.

Authors:  O Le Saux; K Beck; C Sachsinger; C Silvestri; C Treiber; H H Göring; E W Johnson; A De Paepe; F M Pope; I Pasquali-Ronchetti; L Bercovitch; A S Marais; D L Viljoen; S F Terry; C D Boyd
Journal:  Am J Hum Genet       Date:  2001-08-31       Impact factor: 11.025

3.  Folding and rescue of a cystic fibrosis transmembrane conductance regulator trafficking mutant identified using human-murine chimeric proteins.

Authors:  Ana Carina Da Paula; Marisa Sousa; Zhe Xu; Elizabeth S Dawson; A Christopher Boyd; David N Sheppard; Margarida D Amaral
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

4.  The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis.

Authors:  Patrick H Thibodeau; John M Richardson; Wei Wang; Linda Millen; Jarod Watson; Juan L Mendoza; Kai Du; Sharon Fischman; Hanoch Senderowitz; Gergely L Lukacs; Kevin Kirk; Philip J Thomas
Journal:  J Biol Chem       Date:  2010-07-28       Impact factor: 5.157

5.  Protein kinase A regulates ATP hydrolysis and dimerization by a CFTR (cystic fibrosis transmembrane conductance regulator) domain.

Authors:  L Daniel Howell; Roy Borchardt; Jolanta Kole; Andrew M Kaz; Christoph Randak; Jonathan A Cohn
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

6.  Expression and localization of cystic fibrosis transmembrane conductance regulator in the rat endocrine pancreas.

Authors:  Alain Boom; Pascale Lybaert; Jean-François Pollet; Paul Jacobs; Hassan Jijakli; Philippe E Golstein; Abdullah Sener; Willy J Malaisse; Renaud Beauwens
Journal:  Endocrine       Date:  2007-11-27       Impact factor: 3.633

7.  Development of CFTR Structure.

Authors:  Anna E Patrick; Philip J Thomas
Journal:  Front Pharmacol       Date:  2012-09-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.